Acute hepatitis due to buprenorphine administration

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 10, 2004, Pages 1033-1037

  Hervé, Sophie ^a,b   Riachi, Ghassan ^a   Noblet, Catherine ^a   Guillement, Nathalie ^a   Tanasescu, Stephana ^a   Goria, Odile ^a   Thuillez, Christian ^a   Tranvouez, Jean Luc ^a   Ducrotte, Philippe ^a   Lerebours, Eric ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b HÔPITAL CHARLES NICOLLE   (France)

Author keywords

Buprenorphine; Drug addiction; Hepatitis C virus; Hepatotoxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPRAZOLAM; BUPRENORPHINE; HYDROXYZINE; LEVOMEPROMAZINE; SILYMARIN; VALPROIC ACID; VIRUS RNA; ZOPICLONE;

ACUTE HEPATITIS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOLYSIS; DIAGNOSTIC IMAGING; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; FRANCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; JAUNDICE; MALE; PATIENT MONITORING; PRIORITY JOURNAL; REMISSION; SEROLOGY;

ACUTE DISEASE; ADMINISTRATION, SUBLINGUAL; ADULT; BUPRENORPHINE; CAUSALITY; FEMALE; HEPATITIS C; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MITOCHONDRIA, LIVER; NARCOTIC ANTAGONISTS; SUBSTANCE-RELATED DISORDERS;

EID: 6944235860     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200410000-00013     Document Type: Article

References (21)

1. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine and nalorphine like drugs in the non-dependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197:517-532.
2. Hirschauer C, Guillemot F, Héraud M, Mathieu-Chandelier C, Cortot F, Paris JC. Is buprenorphine hepatotoxic? [Letter]. Gastroenterol Clin Biol 1989; 13:636.
3. Berson A, Gervais A, Cazals D, Boyer N, Durand F, Bernuau J, et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001; 34:346-350.
4. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplo N, et al. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-435.
5. Danan G, Benichou C. Causality assessment of adverse reactions to drugs. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46:1323-1330.
6. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22:145-156.
7. Lewis JH, Zimmerman HJ. Drug- and chemical-induced cholestasis. Clin Liver Dis 1999; 3:433-464.
8. Corrao G, Bagnardi V, Zambon A, Torchio P. Meta-analysis of alcohol intake in relation to risk of liver cirrhosis. Alcohol Alcohol 1998; 33: 381-392.
9. Lucidarme D, Foutrein P, Creusy C, Forsy G, Foutrein-Comes MC, Muyssen A, et al. Prevalence of hepatitis C, B and D markers and histopathological aspects in a group of intravenous drug addicts. Gastroenterol Clin Biol 1994; 18:964-968.
10. Puoti M, Zonaro A, Ravaggi A, Marin MG, Castelnuovo F, Cariani P. Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. Hepatology 1992; 16:877-881.
11. Biour M, Poupon R, Grange JD, Chazouilleres O, Jaillon P. Drug-induced hepatotoxicity. Eleventh update of the bibliographic database on liver injuries and responsible drug. Gastroenterol Clin Biol 1998; 22: 1004-1044.
12. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson R. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984; 12:577-581.
13. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55:569-580.
14. Berson A, Frau D, Fornacciari R, Degove-Goddard P, Sutton A, Dascatoire V, et al. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol 2001; 34:261-269.
15. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4:1065-1067.
16. Somasundaran M, Zapp ML, Beattie LK, Pang L, Byron KS, Bassell GJ, et al. Localization of HIV RNA in mitochondria of infected cells: potential role in cytopathogenicity. J Cell Biol 1994; 126:1353-1360.
17. Jacotot E, Ravagnan L, Loeffler M, Ferri KF, Vieira HLA, Zamzani N, et al. The HIV viral protein induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 2000; 191:33-45.
18. Takada S, Shirakata Y, Kaneniwa N, Koike K. Association of hepatitis B virus X protein with mitochondria causes mitochondrial aggregation at the nuclear periphery, leading to cell death. Oncogene 1999; 18: 6965-6973.
19. Pessayre D, Feldmann G, Haouzi D, Fau D, Moreau A, Neumann M. Hepatocyte apoptosis triggered by natural substances (cytokines, other endogenous molecules and foreign toxins). In: Cameron RG, Feuer G (editors): Apoptosis and its Modulation by Drugs. Handbook of Experimental Pharmacology. Berlin: Springer-Verlag; 2000, pp. 59-108.
20. Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999; 15:367-373.
21. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, et al. Antituberculous drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Resp Crit Care Med 1998; 157:1871-1876.